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Abstract
Sepsis is a leading cause of death. Rapid and accurate identification of pathogens and
antimicrobial resistance directly from blood culture could improve patient outcomes.
The FilmArray® (FA; Idaho Technology, Inc., Salt Lake City, UT) Blood Culture (BC) panel can
identify > 25 pathogens and 4 antibiotic resistance genes from positive blood cultures in 1 hour.
We compared a development version of the panel to conventional culture and susceptibility testing
on 102 archived blood cultures from adults and children with bacteremia. Of 109 pathogens
identified by culture, 95% were identified by FA. Among 111 prospectively collected blood
cultures, the FA identified 84 of 92 pathogens (91%) covered by the panel. Among 25
Staphylococcus aureus and 21 Enterococcus species detected, FA identified all culture-proven
MRSA and VRE.
The FA BC panel is an accurate method for the rapid identification of pathogens and resistance
genes from blood culture.
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Sepsis is a leading cause of death in U.S. adults and children (Kochanek, et al., 2011).
Prompt initiation of appropriate antimicrobial therapy is associated with improved outcomes
(Bochud, et al., 2001; Dellinger, et al., 2008; Kumar, 2009). Definitive identification of the
causative organism through traditional culture methods often requires 24–72 hours. This
delay can lead to administration of either inadequate or overly broad antimicrobial therapy.
Inappropriate antimicrobial selection may result in therapy-related complications,
emergence of antimicrobial resistance, and increases in patient morbidity, mortality, and
costs (Bauer, et al., 2010; Bochud, et al., 2001; Dellinger, et al., 2008; Kumar, 2009).
Continuously monitoring automated blood culture systems have enabled the detection of
most blood stream pathogens within 24 hours of inoculation (Cockerill, et al., 2004).
Automated systems for identification and susceptibility testing are available, however the
organism must be isolated in pure culture prior to using them (Jorgensen and Ferraro, 2009).
This requires a minimum of 12–24 hours after the blood culture becomes positive, and
methods to improve bacterial growth rates are lacking (Mancini, et al., 2010).
Identification of pathogens directly from positive blood culture is one proposed solution.
Ideally for such identification, rapid, species-specific identification of a wide range of
pathogens would be provided. For PCR-based systems, this requires a high level of
multiplexing that has been difficult to achieve (Mackay, 2004; Persson, et al., 2005). Here
we describe the preliminary development of such an assay based on Idaho Technology’s
FilmArray® Platform (Poritz, et al., 2011), a closed diagnostic system allowing high-order
multiplex PCR analysis with automated read-out of results. The assay described can identify
15 species-specific and 6 genus level targets, encompassing almost 95 percent of organisms
commonly found in positive blood cultures (Biedenbach, et al., 2004). Four antibiotic
resistance determinants are also included. Design of the assay panel as well as initial testing
of a development version with clinical samples is presented.
Materials and Methods
The Institutional Review Boards of the University of Utah and Primary Children’s Medical
Center (PCMC, Salt Lake City, UT) approved this study. Informed consent was waived.
FilmArray®
The FDA approved FilmArray (FA) System has been described (Poritz, et al., 2011).
Briefly, it is a closed diagnostic system that combines nucleic acid extraction from clinical
specimens, high-order nested multiplex PCR, and post-PCR DNA melt curve analysis.
Panel Design
Nested and nested multiplex PCR—The FA system performs a “nested multiplex”
PCR (nmPCR) within the instrument (Poritz, et al., 2011). Briefly, nmPCR is a 2-stage PCR
in which the first-stage reaction is a multiplex that produces a 200–500 bp amplicon for each
target. The second-stage primers are “nested” within this amplicon and amplify a shorter
product. Nested PCR provides increased sensitivity compared with conventional PCR; the
specificity is similar to probe-based assays (Narayanan, 1996). Assays were developed to
function within the context of nmPCR, with first-stage multiplex amplification performed
for 20 cycles and the array of second stage singleplex nested PCRs performed for 25 cycles.
Panel Design—Organisms were chosen for the BC panel based on laboratory data
provided by our collaborating microbiology laboratory director (JAD) and through review of
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SENTRY data regarding organism prevalence in blood cultures (Biedenbach, et al., 2004).
Both organisms with a high frequency and low pathogenicity [i.e. coagulase-negative
staphylococci (CONS)] and those with a low frequency and high pathogenicity (i.e.,
Neisseria meningitidis) were included. The panel used in the studies presented here includes
15 species-specific targets and 6 genus-level assays. This panel (Table 1) represents ~90–
95% of all pathogens identified from participating laboratories and the SENTRY database.
Antibiotic resistance targets were chosen based on frequency of detection, implications for
change in antibiotic therapy, and the likelihood of a direct correlation between gene
presence and antibiotic resistance. The genes mecA, van A, van B and the Klebsiella
pneumoniae carbapenemase (blaKPC) were included in the panel (Cole, et al., 2009; Fluit, et
al., 2001). In the version of the panel used for clinical validation, the vanC gene was also
included, however this gene was removed from the panel used for the prospective study due
to its low prevalence and association with a variable resistance phenotype (Clark, et al.,
1998).
For species-specific bacterial targets such as virulence factors, genes were chosen based on a
review of the literature. For genus (i.e. “Streptococcus spp.”) or family (i.e.
“Enterobacteriaceae”) level assays, conserved housekeeping genes were targeted and
degenerate primers were designed to encompass important species within the group. For
example, the Streptococcus species assay targets the RNA polymerase β subunit (rpoB) gene
and was designed to capture 7 species in the target alignment. Primers for antibiotic
resistance genes are all located in conserved regions so that only one set contains degenerate
bases (vanA gene; 2-fold degeneracy). The developmental panel used in these studies
includes 50 first-stage primers in the multiplex and 65 second-stage singleplex PCRs.
Primer Design—Gene sequences were obtained through the National Center for
Biotechnology Information’s GenBank Database (Benson, et al., 2011; Sayers, et al., 2011).
Alignments were created and analyzed using Lasergene® software (DNASTAR, Madison,
WI). Primers were designed using LightCycler® Primer Probe Design Software (Roche
Applied Science, Indianapolis, IN). Degenerate primers were used in primer design in cases
where species were divergent within the gene target and in genus-level assays.
Assay optimization
Assay optimization was performed as previously described for FilmArray system
development (Poritz, et al., 2011).
Bacteria and Yeast Isolates—Bacteria and yeast isolates were obtained from the PCMC
microbiology laboratory and from the University of Utah’s Associated Regional and
University Pathologists (ARUP) Laboratories (Salt Lake City, UT). Clinical isolates were
identified by standard microbiologic methods (see below). In addition isolates were obtained
from the American Type Culture Collection (ATCC; Manassas, VA) and from JMI
Laboratories (North Liberty, IA).
Assay validation—All assays were validated for sensitivity and specificity as individual
real-time PCR reactions and in the FA pouch with bacterial isolates and their extracted
nucleic acids. For the Blood Culture (BC) panel described, targets analyzed in the FA
included known positives for each pathogen at levels of approximately 100 – 10,000
genomes per pouch based on DNA fluorimeter measurements (Qubit Fluorimeter, Life
Technologies, Grand Island, NY). Testing was also performed with bacteria/yeast isolates
(2–3 colonies resuspended in 500 μl of the sample buffer). For species-specific assays,
testing was performed with at least 5 different isolates of each organism. Specific
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amplification of targets was evaluated by testing against “nearest neighbors” (ie, testing of
the S. pneumoniae assay against viridans streptococci, S. pyogenes and S. agalactiae). Genus
or group level assays were tested with 1–5 isolates of each target organism within the group.
All assays in the developmental panel had a sensitivity of <100 genomes per pouch and
100% species-or genus-level specificity for bacterial isolates tested (data not shown).
Blood Culture Analyses
Conventional microbiology at Primary Children’s Medical Center (PCMC) and
the University of Utah’s Associated Regional and University Pathologists
(ARUP) Laboratories—Both PCMC and ARUP are Clinical Laboratory Improvement
Amendments (CLIA) certified. In both laboratories, blood culture is performed using the
BACTEC automated blood culture system (BD Diagnostic Systems, Franklin Lakes, NJ).
Cultures signaling positive are removed immediately from the instrument and Gram-stain is
performed within 15 minutes. Isolates of bacteria and yeast are grown on solid media and at
PCMC are identified by VITEK® (bioMerieux, Inc., Durham, NC) and by bench top
biochemical testing. At ARUP, isolates are identified by Phoenix automated identification
system (BD Diagnostic Systems), bench top biochemical testing and/or 16S rRNA gene
sequencing. Antibiotic susceptibility is performed at PCMC by VITEK and by E-Test®
(bioMerieux, Inc.) and at ARUP by the Phoenix (BD Diagnostic Systems), manual broth
microdilution (Trek Diagnostic Systems, Inc., Cleveland, OH), and/or E-Test®. PCR is
performed at ARUP for identification of the mecA gene.
Collection of Blood Culture Samples—1.5 ml samples from blood culture bottles (BD
Diagnostic Systems, Franklin Lakes, NJ) signaling positive were collected from PCMC and
from ARUP Laboratories. Sample collection was initiated at the onset of panel development
and samples were stored frozen at −80 °C until testing.
Validation Study
A validation designed to demonstrate the accuracy of pathogen identification from clinical
blood cultures was performed using blood culture specimens obtained and frozen in 2006–
2007 from PCMC. De-identified samples were chosen to represent the majority of pathogens
on the development version of the FA BC panel by an investigator (AJB) aware of the
culture result, and were tested using the FA by an investigator who was blinded to the
culture results (CH).
Prospectively Collected Sequential Samples
The utility of the panel for identification of pathogens commonly encountered in the clinical
setting was evaluated through prospectively collected sequential samples from all positive
blood cultures obtained between June and August 2010 from PCMC and ARUP. As the
intended use of the panel in the clinical laboratory is to test samples that signal positive in
the automated blood culture system, negative blood cultures were not specifically tested.
Testing was performed, however, if a culture bottle signaled positive, even if organisms
were not seen on Gram stain. When more than one sample was collected from a single
patient, only the first positive sample was analyzed. Samples were de-identified and frozen
within 2 hours of the blood culture signaling positive. All investigators testing samples on
the FA were blinded to culture results.
Data Analysis
FA Results—Automated calls for the assays in the FA BC pouch were made using a beta
version of the FA software (Poritz, et al., 2011) tuned for the BC pouch. Two investigators
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(AJB and CH) confirmed all automated calls based on examination of amplification and
melt curves.
In this developmental pouch version we observed low-level background contamination of
reagents and the pouch. This is a common problem of broad-range PCR-based bacterial
detection systems (Chang, et al., 2011; Corless, et al., 2000; Millar, et al., 2002; Philipp, et
al., 2010; Sontakke, et al., 2009). Contaminants demonstrated late amplification [after 22
cycles in the second stage PCR (36 cumulative first + second stage cycles)] but generated
positive calls by the software. Contaminants were consistent across a production lot of
pouches and were identified by positive calls in the 3–5 negative control (water) runs
performed for each lot. With this information, positive software calls were classified as
contamination if a run was positive for a known lot-contaminating organism and the cycle
crossing point was > 22 cycles in the second-stage PCR.
Statistical analysis—For both the validation and prospective studies sensitivity and
specificity were calculated for the BC panel overall and for each pathogen on the BC panel
independently. 95% confidence intervals were calculated according to the efficient-score
method (corrected for continuity) (Newcombe, 1998). Blood culture was considered the gold
standard. A FA test positive was identified when the FA BC assay was positive for a
pathogen, and a true positive was identified when the blood culture was positive for the
same pathogen. For specificity calculation, all samples negative for a particular pathogen
were included.
Results
Clinical validation study using retrospectively collected positive blood cultures
Initial validation of the BC panel was performed on 102 clinical blood culture samples
selected to be positive for organisms representing the majority of panel pathogens. These
samples were tested retrospectively. Sixteen different pathogens were represented. No
clinical specimens containing Listeria monocytogenes, Acinetobacter baumanii or Candida
spp. were available in this study set and thus these are not included in Table 2. Due to the
wide confidence intervals around the point estimates of sensitivity, these results are reported
with an asterisk for organisms with < 5 clinical samples available (Table 2). Organisms
containing vanA/B/C and mecA were tested, but no organisms were found either by culture
or FA to be carbapenem-resistant or to contain blaKPC.
From 102 clinical specimens, 109 pathogens were identified by culture (7 cultures were
positive for more than one organism). Of the 109 pathogens identified by culture, 104 (95%)
were also identified by FA. Three pathogens identified by FA were not identified by culture.
Sensitivity for each pathogen ranged from 83–100% and specificity was 99% or greater for
all. (Table 2)
The culture-positive/FA-negative discordant samples were analyzed using standard PCR. In
2 cases the specimen was also negative using both an alternative organism-specific assay as
well as broad-range (16S) PCR, suggesting a mislabeled or incorrect culture sample. In two
discordant samples in which culture and FA identified different pathogens, standard PCR
and sequencing demonstrated that the organism identified by FA was correct. In one case of
a culture-identified CONS missed by FA, the organism could not be detected using
alternative PCR strategies. In the case of a FA-identified CONS not identified by culture,
sequencing confirmed the presence of S. epidermidis.
Antibiotic resistance testing demonstrated good concordance with conventional
susceptibility data. Thirteen S. aureus were identified by both culture and FA, of which 4
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were methicillin-resistant S. aureus (MRSA) by susceptibility testing. The FA appropriately
identified all S. aureus as MSSA (mecA negative) or MRSA (mecA positive). Of 13
enterococci identified, one was found by culture to be vancomycin-resistant (VRE) and
positive for vanA/B/C by FA. Two enterococci tested susceptible to vancomycin in the
microbiology laboratory but tested positive for vanA/B/C by FA. One of these isolates was
identified by culture, standard PCR, and sequencing as E. faecium. PCR and sequencing also
demonstrated the vanA gene to be present, with E. faecium-specific vanA polymorphisms
based on alignment to sequences in GenBank. The other sample, identified by culture as
vancomycin-susceptible E. faecalis, was identified by sequencing as E. casseliflavus
containing the vanC gene.
Prospective analysis of sequentially collected samples
One hundred eleven blood culture samples were tested in this study (Table 3). Ninety-three
were culture-positive. Eighteen were Gram-stain and culture-negative despite signaling
positive on the automated blood culture machine. The 93 positive cultures grew 99
organisms (6 dual-positive cultures), of which 92 (93%) were pathogens included in the BC
panel. Seven were positive for non-panel organisms [Micrococcus spp. (n=3);
Corynebacterium spp., Fusobacterium nucleatum, Propionibacterium acnes, Diptheroids
(n=1 each)]. In this study set there were no samples positive by culture or FA for L.
monocytogenes, E. cloacae, N. meningitidis or H. influenzae and no pathogens contained
blaKPC.
The FA identified 84 of the 92 (91%) BC pathogens identified by culture. Sensitivity varied
by organism, and some organisms were rarely seen, but all assays had high specificity
(Table 3). The overall likelihood ratio positive for the test was 4 and the likelihood ratio
negative was 0.11.
In two instances, a culture was positive for two different organisms of the same genus [2
different species of viridans streptococci (n = 1) and 2 species of CONS (n = 1)]. These
could not be resolved by the genus-level PCR and were not counted as discordant results.
FA accurately identified all S. aureus as MSSA or MRSA and all enterococci as susceptible
or resistant to vancomycin. Except for one coagulase-negative staphylococcus detection by
FA, all culture-negative samples and those positive for pathogens not in the BC panel were
negative by FA.
FA did not identify eight pathogens identified in the 92 blood cultures. In six instances
(6.5%) these were shown to be FA false-negatives. In three of these cases (2 yeast and 1
Enterococcus spp.) standard PCR with an increased number of cycles identified the
organism. In two cases, samples positive for CONS by culture were negative by the CONS
FA assay, although the mecA gene PCR was positive. In one case, S. marcescens identified
in culture was not detected by FA or with an increased number of cycles in standard PCR,
but was found by both culture and PCR in subsequent blood cultures from the same patient.
Three of the 8 (37.5%) missed organisms were in dual-positive cultures; FA correctly
identified one of the pathogens but did not detect the second. In 2 instances, primer cross-
reactivity resulted in misidentification of organisms: in one culture positive for Salmonella
enterica the FA misidentified the organism as Klebsiella oxytoca; in another case, FA
identified CONS as well as S. aureus in a culture positive for S. aureus alone. The CONS
identification was confirmed to be a cross-amplification of this particular S. aureus by the
CONS primers.
Seven pathogens identified by FA were not identified by culture. While 2 were the result of
the primer cross-reactivity described above, the other five organisms identified by FA but
not by culture were likely true positives. In one case, Gram stain of BACTEC bottles
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showed Gram-negative rods, but no growth was detected on culture. FA identified two
organisms, E. coli and Acinetobacter baumanii, both of which were confirmed by standard
PCR and sequencing. In two cases, the FA identified a second organism in cultures that
yielded growth for only one organism. In the first, S. aureus was detected by FA in a sample
also culture and PCR positive for GAS. In the second, S. mitis/oralis was detected by FA in
a sample also culture and PCR positive for CONS. In each case, the presence of both
pathogens was confirmed by PCR and sequencing. Finally the FA identified a CONS that
was confirmed by PCR and sequencing to be present in a clinical specimen that was
negative by culture.
Discussion
Rapid identification of organisms causing sepsis is critical to reducing inappropriate
antibiotic use and infection-related morbidity and mortality. Here we describe preliminary
development and clinical testing of a novel molecular diagnostic test for the identification of
organisms in positive blood culture based on the FilmArray® System (Poritz, et al., 2011).
The FA BC panel identifies a wide range of bacterial and fungal pathogens, accounting for
93% of organisms isolated from clinical specimens in our study. In addition, the panel
identifies select antibiotic resistance genes, including those responsible for resistance to
methicillin, vancomycin and carbapenems. Identification of pathogens and resistance
markers was achieved from clinical samples with good sensitivity and specificity for all
targets. An analysis of prospectively obtained blood cultures demonstrated accurate
identification of 91% of pathogens and 100% of MRSA and VRE. When fully developed,
this technology has the potential to contribute significantly to improvements in the
management of adults and children with sepsis.
Rapid molecular identification of organisms from positive blood cultures is increasingly
available in clinical laboratories. Both PCR and probe-based platforms are commercially
available, but all have limitations. In the U.S., the Xpert® MRSA/SA BC assay (Cepheid,
Sunnyvale, CA) and the fluorescence in situ hybridization method employing novel peptide-
nucleic acids as probes (PNA-FISH®; AvanDx, Woburn, MA) are available, but both target
limited numbers of organisms or require several panels (Hensley, et al., 2009; Morgan, et
al., 2010; Shepard, et al., 2008). In Europe, bacterial detection methods from blood culture
based on broad-range PCR are available that target a larger range of organisms in a single
assay, but downstream identification using ELISA (Hyplex®; Cepheid Benelux, Bouwel,
Belgium) or microarray hybridization (Prove-it™ Sepsis; Mobidiag, Helsinki, Finland) is
required. One of the most comprehensive systems under investigation is based on matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry (La
Scola and Raoult, 2009; Stevenson, et al., 2010). MALDI-TOF has the advantage of rapid
turn-around time, modest sample preparation, and the ability to directly identify a large
range of microorganisms. Disadvantages include the high start-up costs associated with the
purchase of mass-spectrometry equipment and training of personnel.
Identification of blood culture pathogens using the FilmArray® System’s BC panel has
several advantages. A particular strength is the large number of targets, all evaluated in a
single test, covering the majority of organisms detected in both adult and pediatric blood
cultures. In this study, organisms identified by blood culture but not contained in the FA BC
panel primarily included those often considered contaminants, such as diphtheroids and
micrococcus. In addition, the FA System performs all steps of the assay, from nucleic acid
extraction to interpretation of amplification data in closed system using a single pouch on a
minimally processed clinical sample. The laboratory procedures required are not
technologically complex and can be performed by persons who do not have training in
molecular techniques (Poritz, et al., 2011).
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Our clinical validation study of 102 retrospectively-collected blood culture samples
demonstrated accurate identification of most pathogens. In the primary analysis there were 8
discordant identifications (5 culture+/FA−; 3 culture−/FA+), however all but one
identification (of CONS) could be resolved in favor of the FA. Specificity was high for all
pathogens, including species-specific and genus-level targets. Specificity was comparable to
that of the VITEK2 for cultured organisms, for which the accuracy of identification ranges
from 92–97% (Abele-Horn, et al., 2006; Nonhoff, et al., 2005; O’Hara and Miller, 2003;
Rennie, et al., 2008).
The FA BC panel also contains antibiotic resistance markers. MRSA is a well-described
health-threat (Klevens, et al., 2007), and a number of commercially available panels can
distinguish MRSA from methicillin-susceptible strains through the identification of the
mecA gene that is also identified in our panel. While in Europe a Nanosphere panel
(Verigene System, Nanosphere, Northbrook IL) is available for detection of the primary
genetic determinants of vancomycin-resistance in enterococci [vanA and vanB] (Courvalin,
2006), no commercially available panels approved for blood culture in the U.S. contain
assays for vanA and vanB or carbapenem-resistance in enteric organisms [blaKPC]
(Nordmann, et al., 2009).
In choosing resistance targets for the BC panel, we chose genes in which detection of the
resistance marker almost always indicates a phenotypically drug-resistant organism. We had
one true genotype-phenotype discordance detected with regard to vancomycin susceptibility
in our validation study: an E. faecium that was PCR positive for vanA, yet phenotypically
vancomycin-susceptible. This discordance has been rarely reported (Choi, et al., 2011).
Our prospective study of consecutively collected samples was designed to evaluate the
performance of the system on an unbiased selection of positive blood cultures. Overall, the
system performed well, although the sensitivity was lower for Serratia marcescens (1/2),
broad Enterobacteriaceae detection (3/4) and yeasts (4/6). The small numbers of samples
preclude accurate assessment of the sensitivity for these organisms, however for others,
sensitivity was good (88–100%). Specificity was >98% for all organisms.
There are limitations to the BC system at this point in development. While comprehensive,
the FA BC panel does not detect all possible organisms. This reflects both a limitation in the
number of assays that could be placed into the multiplex, and a conscious decision to
primarily target organisms that occur at a high enough frequency to support FDA clearance.
Sensitivity was not an issue for most organisms, however two of six Candida species
detected in culture were not detected by FA. We hypothesized that yeast might signal
“positive” at lower titers in automated blood culture systems. We performed growth studies
in which the concentration of yeast at the time of culture positivity ranged from 103 – 107
CFU/ml rather than the 107 – 1011 seen with bacteria (Tan, et al., 2008) similar to another
published report (Chang, et al., 2000). For this reason we are evaluating multi-copy rather
than single-copy targets for yeast detection.
Polymicrobial culture was the most common reason that a cultured organism went
undetected by PCR. Approximately 7% of blood cultures in the prospective study were
polymicrobial, however in three of eight (38%) instances in which the FA did not detect a
pathogen, the blood culture was positive for two organisms. We speculate that in cultures
positive for two organisms, one may grow more rapidly and trigger a positive signal in the
culture system. At the time of the positive call, the second organism may be below the level
of molecular detection.
As often reported for PCR-based detection systems that evaluate a broad range of bacteria,
contamination of reagents and materials was an issue in this developmental version of the
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system (Chang, et al., 2011; Corless, et al., 2000; Millar, et al., 2002; Philipp, et al., 2010;
Sontakke, et al., 2009). This is most often reported for 16S PCR-based detection, however in
our system we have specific assays for potentially contaminating bacteria such as CONS and
E. coli. At the level of research and development this was not a significant issue for
evaluation of the sensitivity and specificity of the panel. In positive blood cultures, second
stage crossing thresholds for culture-identified organisms were generally in the range of 13–
16 cycles. The level of contamination in the pouches was quite low, with second stage PCR
crossing thresholds beyond 22 cycles [36 cumulative cycles] or signal only detected by the
presence of a melting curve. Current development efforts are focused on eliminating
detectible contamination through improvements in manufacturing as well as software cutoffs
for commonly contaminating organisms. Overall system sensitivity must be maintained for
the detection of yeasts and polymicrobial cultures as previously discussed.
A primary limitation of this study was the low number of samples positive for some
organisms. While nucleic acid testing demonstrated good sensitivity and specificity of
assays such as those for L. monocytogenes, N. meningitidis and H. influenzae, the low
number of positive blood culture specimens makes clinical sensitivity hard to determine. In
addition, there were no clinical specimens demonstrating carbapenem resistance or that were
positive by PCR for blaKPC. Additional studies, including at sites with higher rates of
resistance will be necessary for clinical evaluation of these assays.
Overall the FA BC panel demonstrated accurate identification of pathogens found in
positive blood cultures from both adult and pediatric patients. This panel identifies a larger
range of pathogens than most currently available platforms in a system that is technically
simple for the laboratory. The data presented here suggest that the FA BC system could be
an important and useful tool for the management of bloodstream infection in the future.
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Table 1
Organisms Contained within the Developmental FilmArray BC panel
Organism Gene 1 Gene 2
Gram Positive









Escherichia coli gyrB ompA
Klebsiella oxytoca gyrB ompA
Klebsiella pneumoniae gyrB ompA
Enterobacter cloacae gyrB ompA
Serratia marcescens gyrB ompA
Enterobacteriaceae4 ompA
Neisseria meningitidis ctrA
Haemophilus influenzae rpoB bexA
Pseudomonas aeruginosa gyrB









vanC gene included in panel used for the validation study, but subsequently removed.
1
Streptococcal species included for primer design were: S. pneumoniae, S. parasanguinis, S. anginosus, S. salivarius, S. pyogenes, S. uberis, S.
mitis, S. sanguis, S. mutans, S. oralis, S. equinis, S. gordonii, S. gallolyticus
2
Coagulase-negative staphylococci included for primer design were: S. epidermidis, S. hominis, S. haemolyticus, S. capitis, S. saprophyticus, S.
warneri, S. xylosus, S. caprae, S. cohnii, S. koosii, S. saccrolyticus, S. nepalensis, S. microti, S. simiae, S. lugdunensis
3
Enterococcal species included for primer design were: E. facaelis, E. faecium, E. casseliflavus, E. durans, E. gallinarum
4
Enterobacteriaceae included for primer design were: E.coli, E. hermannii, E. fergusonii, Shigella sonnei, S. boydii, S. dysenteriae, S.flexneri, C.
freundii, Salmonella enterica, S. typhimurium, Enterobacter. aerogenes, E. cloacae, E. sakazaki, Klebsiella. oxytoca, K.pneumoniae, Serratia.
marcescens
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5
Non-albicans candida included are: C. parapsilosis, C. glabrata, C. tropicalis, C. krusei
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